At the 61st ASH Annual Meeting & Exposition, Louis Williams, NYU Langone Medical Center, provides a snapshot of his recent article with Oncology & Hematology (US) exploring genetic segmentation and targeted therapeutics for multiple myeloma.
Questions
1. How has increased understanding of the molecular biology of multiple myeloma impacted on risk stratification of patients? (0:05)
2. Could you tell us a little about B-cell maturation antigen targeted therapies? (1:02)
3. What other emerging targeted therapies seem promising? (2:34)
4. With so many new therapies available, how can we best incorporate them into the treatment paradigm? (3:56)
5. What other pathways are potential therapeutic targets? (5:28)
Louis Williams has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
